Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
4.905
-0.015 (-0.30%)
At close: Apr 28, 2026, 4:00 PM EDT
4.905
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Aptevo Therapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Aptevo Therapeutics.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Aptevo Therapeutics.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $199,800 → $106,560 | Strong Buy | Maintains | $199,800 → $106,560 | +2,172,377.06% | Sep 23, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $40,439,520 → $11,721,600 | Buy | Maintains | $40,439,520 → $11,721,600 | +238,972,377.06% | May 13, 2022 |
| Roth Capital | Roth Capital | Strong Buy Maintains $37,509,120 → $29,304,000 | Strong Buy | Maintains | $37,509,120 → $29,304,000 | +597,431,092.66% | May 28, 2021 |
| Piper Sandler | Piper Sandler | Buy Maintains $18,754,560 → $40,439,520 | Buy | Maintains | $18,754,560 → $40,439,520 | +824,454,945.87% | Nov 11, 2020 |
| Roth Capital | Roth Capital | Strong Buy Initiates $98,461,440 | Strong Buy | Initiates | $98,461,440 | +2,007,368,707.34% | Apr 11, 2018 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-21.41
from -82.30
EPS Next Year
-19.02
from -21.41
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | n/a | n/a | |||||
| Avg | n/a | n/a | |||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | - | - | |||||
| Avg | - | - | |||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | -22.04 | -19.58 | |||||
| Avg | -21.41 | -19.02 | |||||
| Low | -20.57 | -18.28 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | - | - | |||||
| Avg | - | - | |||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.